In the published article, there was an error in the Funding statement. Missing grant supporting this manuscript. The correct Funding statement appears below.
Funding
“Thanks to Immunology department (Hospital Clínic de Barcelona) and Institute of Biotechnology and Biomedicine (IBB-UAB) for their help during the writing of this article. This work has been partially supported by grants from the Instituto de Salud Carlos III, Spanish Ministry of Health (FIS PI18/00775, PICI18/00012 and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional (FEDER) “una manera de hacer Europa”, “La Caixa” Foundation (CP042702/LCF/PR/GN18/50310007), and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement, Generalitat de Catalunya, project 2020PANDE00079.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
T cells, chimeric antigen receptor (CAR), ligands, receptor, antigen, CAAR, BAR
Citation
Ramírez-Chacón A, Betriu-Méndez S, Bartoló-Ibars A, González A, Martí M and Juan M (2022) Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments. Front. Immunol. 13:1078003. doi: 10.3389/fimmu.2022.1078003
Received
23 October 2022
Accepted
09 November 2022
Published
21 November 2022
Volume
13 - 2022
Edited and reviewed by
Catherine Sautes-Fridman, INSERM U1138 Centre de Recherche des Cordeliers (CRC), France
Updates
Copyright
© 2022 Ramírez-Chacón, Betriu-Méndez, Bartoló-Ibars, González, Martí and Juan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Manel Juan, mjuan@clinic.cat
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.